RATIONAL AND OBJECTIVE: Functional opposition between N-methyl-D-aspartate and 5-HT(2A) receptors may be a neural mechanism supporting cognitive functions. These systems converge on an intracellular signaling pathway that involves protein kinase A-dependent phosphorylation of different proteins including cyclic adenosine monophosphate response element binding (CREB). Thus, we tested whether selective 5-HT(2A) receptor antagonist, M100907, might abolish phencyclidine (PCP)-induced attentional performance deficit by preventing its effects on transduction mechanisms leading to CREB phosphorylation. METHODS: Using the five-choice serial reaction time task, the ability of subcutaneous injections of 2.5 and 10 microg/kg of M100907 to abolish the effects of an intraperitoneal injection of 1.5 mg/kg PCP on attentional performance as measured by accuracy (percentage of correct responses) and anticipatory and perseverative responding was assessed in DBA/2 mice. The effects of PCP, M100907, and their combination on S(133)-CREB and T(34)-DARPP32 phosphorylation in the dorsal striatum and prefrontal cortex (PFC) of behaviorally naïve mice were examined using Western blotting technique. RESULTS: PCP reduced accuracy and increased anticipatory and perseverative responses as well as it increased S(133)-CREB phosphorylation in the dorsal striatum but not in the PFC. Ten microg/kg M100907 abolished the PCP-induced attentional performance deficits and the increase in S(133)-CREB but not T(34)-DARPP32 phosphorylation. By itself, M100907 had no effect on attentional performance or phospho-S(133)-CREB and phospho-T(34)-DARPP32. Interestingly, the effect of PCP on phospho-S(133)-CREB but not on phospho-T(34)-DARPP32 was dependent on endogenous 5-HT. CONCLUSIONS: The data indicate that blockade of 5-HT(2A) receptors may exert beneficial effects on cognitive deficits through a mechanism linked to striatal S(133)-CREB phosphorylation.
RATIONAL AND OBJECTIVE: Functional opposition between N-methyl-D-aspartate and 5-HT(2A) receptors may be a neural mechanism supporting cognitive functions. These systems converge on an intracellular signaling pathway that involves protein kinase A-dependent phosphorylation of different proteins including cyclic adenosine monophosphate response element binding (CREB). Thus, we tested whether selective 5-HT(2A) receptor antagonist, M100907, might abolish phencyclidine (PCP)-induced attentional performance deficit by preventing its effects on transduction mechanisms leading to CREB phosphorylation. METHODS: Using the five-choice serial reaction time task, the ability of subcutaneous injections of 2.5 and 10 microg/kg of M100907 to abolish the effects of an intraperitoneal injection of 1.5 mg/kg PCP on attentional performance as measured by accuracy (percentage of correct responses) and anticipatory and perseverative responding was assessed in DBA/2 mice. The effects of PCP, M100907, and their combination on S(133)-CREB and T(34)-DARPP32 phosphorylation in the dorsal striatum and prefrontal cortex (PFC) of behaviorally naïve mice were examined using Western blotting technique. RESULTS:PCP reduced accuracy and increased anticipatory and perseverative responses as well as it increased S(133)-CREB phosphorylation in the dorsal striatum but not in the PFC. Ten microg/kg M100907 abolished the PCP-induced attentional performance deficits and the increase in S(133)-CREB but not T(34)-DARPP32 phosphorylation. By itself, M100907 had no effect on attentional performance or phospho-S(133)-CREB and phospho-T(34)-DARPP32. Interestingly, the effect of PCP on phospho-S(133)-CREB but not on phospho-T(34)-DARPP32 was dependent on endogenous 5-HT. CONCLUSIONS: The data indicate that blockade of 5-HT(2A) receptors may exert beneficial effects on cognitive deficits through a mechanism linked to striatal S(133)-CREB phosphorylation.
Authors: Michel Barrot; Jocelien D A Olivier; Linda I Perrotti; Ralph J DiLeone; Olivier Berton; Amelia J Eisch; Soren Impey; Daniel R Storm; Rachael L Neve; Jerry C Yin; Venetia Zachariou; Eric J Nestler Journal: Proc Natl Acad Sci U S A Date: 2002-08-06 Impact factor: 11.205
Authors: W A Carlezon; J Thome; V G Olson; S B Lane-Ladd; E S Brodkin; N Hiroi; R S Duman; R L Neve; E J Nestler Journal: Science Date: 1998-12-18 Impact factor: 47.728
Authors: T Koskinen; S Ruotsalainen; T Puumala; R Lappalainen; E Koivisto; P T Männistö; J Sirviö Journal: Neuropharmacology Date: 2000-01-28 Impact factor: 5.250
Authors: Janet M Finlay; Ginger A Dunham; Analiesse M Isherwood; Chelsea J Newton; Thuyanh V Nguyen; Patricia C Reppar; Ilana Snitkovski; Sarah A Paschall; Robert W Greene Journal: Brain Res Date: 2014-10-29 Impact factor: 3.252
Authors: Evan J Kyzar; Christopher Collins; Siddharth Gaikwad; Jeremy Green; Andrew Roth; Louie Monnig; Mohamed El-Ounsi; Ari Davis; Andrew Freeman; Nicholas Capezio; Adam Michael Stewart; Allan V Kalueff Journal: Prog Neuropsychopharmacol Biol Psychiatry Date: 2012-01-09 Impact factor: 5.067